Referred to the House Committee on Energy and Commerce.
This resolution expresses the House of Representatives support for designating June 19, 2026 as World Sickle Cell Awareness Day and encourages public awareness, early screening, research, treatments, and equitable access to care. It urges the President and federal agencies to coordinate on policies and asks the Department of Health and Human Services to support newborn screening, treatments, and global assistance. It does not create new law, funding, or legal obligations and is advisory and non-binding.
This is a House simple resolution that only needs passage in the House; it does not go to the Senate or the President and does not have the force of law.
This House resolution expresses support for designating June 19, 2026, as World Sickle Cell Awareness Day.
It calls for increased public awareness, newborn screening, empirical research, equitable access to innovative therapies (including cell and gene therapies), creation of global policy solutions, and an interagency group to address access and bias in sickle cell disease care.
As a House simple resolution it is symbolic and does not create law; adoption in the House is plausible, legal effect is minimal.
Relative to its intended legislative type, this bill functions chiefly as a commemorative resolution with supplemental administrative requests: it clearly defines the problem and calls out specific agencies and actions, but it remains nonbinding and lacks fiscal, timeline, and accountability detail.
Extent of federal role: symbolic awareness versus expanded coverage obligations
These are examples from the analysis, not a ranked list of the most-affected groups.
Extent of federal role: symbolic awareness versus expanded coverage obligations
Strongly supportive.
The resolution highlights equity, access to novel cures, and addressing bias in healthcare, aligning with priorities for health justice.
It is valued as a symbolic step toward building policy momentum for expanded screening and affordable access to curative therapies.
Generally supportive but pragmatic.
The resolution's awareness, research, and screening goals are constructive, but centrists will seek clarity on costs, implementation, and measurable outcomes.
They will view the interagency coordination idea positively if it includes cost-effectiveness and federal-state roles.
Cautiously supportive of awareness aims but wary of policy implications.
Supporting awareness and research is acceptable; however, calls to alter Medicare/Medicaid access to expensive gene therapies and creating new interagency efforts raise concerns about costs and federal overreach.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
As a House simple resolution it is symbolic and does not create law; adoption in the House is plausible, legal effect is minimal.
The bill has not accumulated any surfaced votes yet.
Extent of federal role: symbolic awareness versus expanded coverage obligations
As a House simple resolution it is symbolic and does not create law; adoption in the House is plausible, legal effect is minimal.
Relative to its intended legislative type, this bill functions chiefly as a commemorative resolution with supplemental administrative requests: it clearly defines the problem and calls out specific agencies and actions,…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.